Research any topic before you write.
Find related topics. | Discover entities. | See connections. | Build a topical map.
Casdatifan is an investigational new drug that is being evaluated by Arcus Biosciences and AstraZeneca for the treatment of renal cell carcinoma. It is an inhibitor of endothelial PAS domain-containing protein 1 (HIF‑2α).
The analysis highlights Science, Pharmacology and Clinical trials as prominent areas in the source structure around Casdatifan.
Source areas are shown by the number of related topics found in each part of the analysis. Use smaller areas too: they can reveal specialized angles and content gaps.
Smaller areas are not necessarily less important. They contain fewer connections in this analysis and can be useful for finding specialized angles or coverage gaps.
High-confidence facts extracted from structured source data. Use them as anchors for further research.
Explore different angles and find fresh ideas to shape your next piece of content.
Search suggestions related to this topic. Open a question to research it further; suggestions are not verified answers.
Browse the complete topic structure, not only the most central items. Less prominent entities and concepts can reveal missing angles, specialized context and useful research gaps. Each item opens a new analysis centered on that subject.
You can skip this section if you’re here for content ideas and keyword inspiration.
The extracted context around Casdatifan shows recurring relationship patterns in the source. For example, Casdatifan → Interactive image Another extracted example is Casdatifan → 2709069-30-5. Use these groups to spot repeated connection types before inspecting the individual relationships.
Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.
inhibitor treatment renal cell carcinoma hif 2α clinical trials astrazeneca investigational new drug evaluated arcus biosciences endothelial pas domain-containing protein
TTTA extracted 14 structured relationships around Casdatifan. Examples in this analysis include Casdatifan → 3D model (JSmol) → Interactive image and Casdatifan → CAS Number → 2709069-30-5. The table shows each extracted connection, where it came from and its confidence.
| Subject | Predicate | Object | Confidence | Src |
|---|---|---|---|---|
| Casdatifan | 3D model (JSmol) | Interactive image | 1.00 | infobox |
| Casdatifan | CAS Number | 2709069-30-5 | 1.00 | infobox |
| Casdatifan | ChEBI | CHEBI:760136 | 1.00 | infobox |
| Casdatifan | ChEMBL | ChEMBL6068220 | 1.00 | infobox |
| Casdatifan | DrugBank | DB21701 | 1.00 | infobox |
| Casdatifan | Formula | C21H17F4NO3S | 1.00 | infobox |
| Casdatifan | IUPHAR/BPS | 13981 | 1.00 | infobox |
| Casdatifan | KEGG | D13257 | 1.00 | infobox |
| Casdatifan | Molar mass | 439.42 g·mol−1 | 1.00 | infobox |
| Casdatifan | Other names | AB-521 | 1.00 | infobox |
| Casdatifan | PubChem CID | 156859185 | 1.00 | infobox |
| Casdatifan | UNII | DP73UWL6LE | 1.00 | infobox |
| Casdatifan | is a | investigational new drug that is being evaluated by Arcus Biosciences and AstraZeneca for the treatment of renal cell carcinoma | 0.90 | text |
The concept neighborhoods around Casdatifan bring nearby vocabulary together. In this analysis, examples include Carcinoma, Cell and Clinical. Use the clusters to find adjacent concepts and terminology that may deserve separate research.
For Casdatifan, one of the stronger structural bridges in this analysis connects Casdatifan with Overview. Bridges highlight paths between different parts of the map and can reveal research angles that are easy to miss in a flat list.
TTTA analyzes the structure around Casdatifan to surface related topics, entities, relationships, concept neighborhoods and bridge connections. Use the map to explore areas such as Science, Pharmacology & Clinical trials, including less central topics that may reveal useful research gaps. Automatically extracted connections are research leads rather than rewritten encyclopedia content.
Source: Wikipedia — Casdatifan · EN edition · Analysis: TopicsToTalkAbout
